Tender Details
Beyond this tender, use our platform to source any product, service, or solution.
Get direct quotes or register as a qualified provider.
| Particulars | Details |
|---|---|
| Title |
Running Contract For Inj. Ranibizumab (10 Mg/Ml) (0.23 Mg/0.23 Ml)for Intravitreal Injection Vial. The Medicine Should Be Approved By Dcgi For Wet Armd, Diabetic Macular Oedema, Rvo, Myopic Cnvm, Pdr And Rop.
|
| Description |
For Complete Deion And Other Details, Please Refer To Tender
|
| Organisation | Ministry of Railways | Central Govt. Ministry/Department |
| Tender Id | 106794964 |
|
Reference Number |
HB256036B |
| Tender Fee | 0 |
| EMD | 57400 |
| Tender Value | |
| Place | Kolkata |
| Link |
View Original Tender Notice
https://www.ireps.gov.in/ireps/supply/pdfdocs/082025/106794964/viewNitPdf_5077359.pdf |
| Start Date | August 13, 2025 17:02 |
| End Date |
Expired
29/08/2025
Expired 307 days ago |
Tender Support
Get help with filing, GeM registration, documents, or relevant tender alerts.
Running contract for inj. ranibizumab (10mg/ml)) (0.23mg/0.23ml) for intravitreal injection vial, the medicine should be approved by dcgi for wet armd, diabetic macular oedema, rvo, myopic cnvm, pdr and rop.
For complete deion and other details, please refer to tender
Read moreInj. ranibizumab (each pfs/ amp/vial contains ranibizumab upto 2.3 mg/ 0.23 ml) {the drug should be dgci approved for diabetic macular oedema, retinal vein occlusion, proliferative diabetic retinopathy, retinopathy of prematurity and myopic choroidal neovascular membrane.}
For complete deion and other details, please refer to tender
Read moreInj. ranibizumabo.23ml, 10mg/ml vial, ra [inj. ranibizumabo.23ml, 10mg/ml vial, ranibizumab biosimilar, the medicine should be approved by dcgi/fda for wet amd, diabetic macular edema, rv0, myopic cnvm ,retinopathy of prematurity and pdr .]
For complete deion and other details, please refer to tender
Read moreInj. ranibizumab 0.23 ml , 10 mg /ml vial/pfs
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - vial/pfs 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRanibizumab 2.3mg inj approved by cdsco for the following indications- 1) wet amd, 2) diabetic macular edema, 3) retinal vein occlusion, 4) myopic cnvm, 5) proliferative diabetic retinopathy
For complete deion and other details, please refer to tender
Read moreRanibizumab intra-vitreal injection 10 mg/ml, 0.23 ml vial/0.165 ml pfs
For complete deion and other details, please refer to tender
Read moreRanibizumab intra vitreal injection - pfs approved for all indications 1.wet age related macular degeneration 2.diabetic macular edema 3.proliferative diabetic retinopathy 4.retinal vascular occlusion 5.myopic choroidal neovascularization 6.retinopathy of prematurity
For complete deion and other details, please refer to tender
Read moreRunning contract for brolucizumab solution for injection 120 mg/ml (vial filter needle) 0.23 ml/27.6 mg.
For complete deion and other details, please refer to tender
Read moreof your Industry type